Dermapharm Holding SE invests in family-owned Austrian pharmaceutical company Montavit – Biotech Investments

Dermapharm Holding SE invests in family-owned Austrian pharmaceutical company Montavit

Grünwald, 13 June 2023 – Dermapharm Holding SE (“Dermapharm”), a rapidly growing manufacturer of branded pharmaceuticals, contractually acquired a significant interest in Pharmazeutische Fabrik Montavit Gesellschaft m.b.H. (“Montavit”), Absam, Tyrol, Austria, via its wholly owned subsidiary Dermapharm AG on 7 June 2023.

Montavit is a family-owned company founded in 1945 that develops and produces pharmaceuticals and medical devices. Montavit specialises in the urology, gynaecology, allergy therapy and herbal pharmaceuticals therapeutic areas and the manufacture of sterile catheter gels.  The parties have agreed to keep the contractual details of the deal confidential.

“Montavit is a very interesting addition to the product range in our core therapeutic areas. In the field of urology in particular, Montavit has been considered a pioneer in catheter gels since the 1970s. With its products marketed under the ‘Cathejell’ brand, Montavit is not just the clear market leader in Austria, but is also highly successful in markets such as Italy, Spain, Israel, Indonesia, South Korea, Australia and South Africa,” said Dr Hans-Georg Feldmeier, Chairman of the Board of Management of Dermapharm Holding SE.

The family owners welcome Dermapharm AG’s investment in Montavit. “This merger has succeeded in safeguarding jobs, the location and efforts to maintain and refine our product portfolio,” enthused Managing Partner Katherina Schmidt. The family owners are thoroughly looking forward to the new venture and the manifold opportunities for development that the synergies bring with them going forward.

The equity investment in Montavit is also a continuation of Dermapharm’s internationalisation strategy: Montavit produces pharmaceuticals and medical devices in accordance with European standards and exports its products to over 80 countries. They are marketed either in-house or via a distribution partner.

The production and filling processes are handled exclusively at the company’s state-of-the-art main factory in Absam, which fits perfectly with Dermapharm’s “Made in Europe” strategy. In addition to its core specialisation producing catheter gels, the company also has long-term expertise in manufacturing and packaging granulates and powders, tablets, coated tables, liquids and suppositories, and also offers this expertise to B2B customers.

Company profile

Dermapharm – Pharmaceutical Excellence “Made in Germany”

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company’s integrated business model comprises in-house development, production and the distribution of brand-name products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.

In the “Branded pharmaceuticals and other healthcare products” segment, Dermapharm has more than 1,200 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm’s portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.

In the “Herbal extracts” segment, Dermapharm can tap the expertise of the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, food supplements and cosmetics industries. At the beginning of 2022, the segment was expanded to include Germany-based C³ Group, which develops, manufactures and markets synthetic cannabinoids. C³ Group is the market leader for dronabinol in Germany and Austria. In January 2023, the segment was expanded to include Arkopharma, the market leader for herbal medicines and food supplements in France.

Dermapharm’s business model also includes the “Parallel import business” segment that operates under the “axicorp” brand. Based on revenue, axicorp was among the top four parallel import companies in Germany in 2022.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, Dermapharm has continuously optimised its business over the past 30 years and sought external growth opportunities in addition to organic growth. Dermapharm is firmly committed to continuing on this profitable growth course in the future.

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 – 64186-233
E-mail: ir@dermapharm.com